Company Directory > CRO > Veeda Lifesciences
Veeda Lifesciences (formerly Veeda Clinical Research) is a leading independent, full-service Contract Research Organization (CRO) headquartered in Ahmedabad, India. The company provides end-to-end drug development solutions, including preclinical research, early and late-phase clinical trials (Phase I-IV), bioequivalence studies, and biopharma services. Following a rebranding in early 2025, the company has expanded its scope from a generics-focused CRO to a broader drug development services provider, incorporating CDMO offerings. Veeda operates globally with a significant footprint in India, Europe, and North America, bolstered by strategic acquisitions such as Bioneeds (preclinical) and Heads (oncology-focused clinical trials).
CLASSIFICATION
Company Type:CRO
Industry:CRO
Sub-Industry:Clinical Research Organization
SIZE & FINANCIALS
Employees:501-1000
Revenue:$50M-$100M
Founded:2004
Ownership:private
Status:operating
FUNDING
Stage:Pre-IPO
Investors:Basil Pvt Ltd, Bondway Investments Inc, Sabre Partners AIF Trust, CX Alternative Investment Fund
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Service Provider)
Modalities:Small molecule, Biotherapeutics, Generics, Biosimilars
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Bioneeds, Heads
Key Partnerships:Cytiva (Biopharma innovation collaboration)
COMPETITION
Position:Challenger
LEADERSHIP
Key Executives:
Mahesh Bhalgat - Group CEO and Managing Director
Ajay Tandon - Managing Director
Board Members:Kiran Vithaldas Marthak, Shankarappa Nagaraja vinaya Babu
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Veeda Lifesciences and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Veeda Lifesciences. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.